Novelty Nobility, Inc.


Novelty Nobility is a biotech company focused on antibody design and discovery, overcoming drug resistance with antibody-drug conjugates, and bringing innovative solutions to healthcare. They are engaged in antibody research, clinical trials, and technological development to advance medical treatments.

Industries

biotechnology
health-care
life-science
therapeutics

Nr. of Employees

small (1-50)

Novelty Nobility, Inc.


Patents

Anti-C-KIT antibody

US-12134646-B2

View Details

Method for conjugating antibody and physiologically active substance

US-11998612-B2

View Details

Method for conjugating antibody and physiologically active substance

US-11723984-B2

View Details

Dual-targeting antibody targeting SCF and galectin-1 and use thereof

US-11377489-B2

View Details

Composition comprising material for inhibiting SCF or receptor thereof for treating or preventing diseases associated with vascular permeability

US-9528112-B2

View Details

Products

Fit-for-purpose antibody design & discovery platform

A platform for designing and discovering therapeutic antibodies, supporting generation of candidate leads and optimization for intended applications.

Antibody-drug conjugate oncology candidates (pipeline)

Antibody-drug conjugate programs targeting cancer indications, with development emphasis on overcoming resistance mechanisms.

Ophthalmic biologics program

Programs focused on developing biologic approaches intended to improve ocular outcomes or aspects of vision.


Services

Provision of platform-driven antibody discovery and optimization services for therapeutic lead generation and fit-for-purpose design.

Development and translational support for ADC programs, including design strategies aimed at mitigating drug resistance.

Expertise Areas

  • Antibody engineering
  • Antibody-drug conjugate development
  • Oncology drug development and clinical translation
  • Ophthalmic biologics development
  • Show More (2)

Key Technologies

  • Antibody engineering
  • Antibody-drug conjugates (ADC)
  • Biologic discovery platforms
  • Ophthalmic biologics
  • Show More (1)

News & Updates

Medico Pharma reports that Novelty Nobility is advancing clinical trials for ADC anticancer drugs in the US.

The company has voluntarily withdrawn its preliminary review for KOSDAQ listing.

Selected by Johnson & Johnson to participate in JLABS Korea.

The company emphasizes ADC as its core competency and discusses strategic technology transfer.

The company has filed for preliminary review and is making efforts to pursue new licensing opportunities.


Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.